To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at For Technical questions please contact Thank you.

Privacy Policy Update

We remain dedicated to protecting your data and experience throughout our platforms. We have updated our Privacy Policy and your continued use of the Site means you have accepted the revised Privacy Policy. View now >

Primary CD4+ Helper T Cells (ATCC® PCS-800-016)

Organism: Homo sapiens, human  /  Tissue: peripheral blood  / 

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue peripheral blood
Morphology spherical
Growth Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease normal
Age lot-specific
Gender lot-specific
Ethnicity lot-specific
Applications Research purposes, compound screening, immune function assays
Product Format frozen 1.0 mL
Storage Conditions liquid nitrogen vapor phase
Comments CD4 Helper T Cells oversee the action of the human immune system; they are involved in activating and directing other immune cells. CD4+ Helper T Cells are crucial in (1) determining B cell antibody class switching, (2) the activation and growth of Cytotoxic T Cells, and (3) maximizing bactericidal activity of phagocytes (i.e., macrophages).
CD4+ Helper T Cells are isolated from mononuclear cells by positive selection using immunomagnetic cell separation procedures.
CD4+ Helper T Cells are tested by flow cytometry for the following surface markers:  
  • CD3+: ≥ 90% 
  • CD4+: ≥ 90% 
  • CD45+: ≥ 90%
Complete Growth Medium CD4+ Helper T Cells have a limited lifespan in culture and should be thawed immediately and only prior to their intended use in application specific media. ATCC recommends thawing them in RPMI-1640 (ATCC 30-2001). ATCC does not recommend maintaining CD4+ Helper T Cells in culture in the absence of application-specific growth factors.
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Volume 1.0 mL
Cells per Vial ≥ 2.5 X 107
Viral Testing Hepatitis B: Negative
Hepatitis C: Negative
HIV: Negative
HTLV-I/II: Negative
C of A
Certificate of Analysis
Certificate of Analysis
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
  1. Human primary immune cells per vial

    Each ATCC vial contains at least 25x106 viable cells.

    Date Updated: 2/26/2018
  2. Cell surface marker expression in Primary CD19+ B Cells (ATCC® PCS-800-018™)

    Each lot is tested for expression of CD45+ and CD20+. Each lot is tested to ensure surface marker expression of ≥90%.

    Date Updated: 3/27/2018
  3. Availability of primary human cells from non‐normal - diseased donors

    Date Updated: 2/26/2018

  4. Cryopreservative used with Primary Immune cells

    ATCC Primary Immune cells are cryopreserved in a serum‐free and xeno‐free medium (CryoStor® CS10 Freeze Medium from BioLife Solutions).

    Date Updated: 2/26/2018
  5. Human primary immune cell expansion

    Yes, with proper stimuli (typically via cytokines and/or under co‐culture conditions) CD4+ Helper

    Date Updated: 2/26/2018
  6. Post-thaw yield and viability of Human Primary Immune cells

    We recommend the following thawing procedure:

    Date Updated: 2/26/2018

Luckheeram RV, et al. CD4+T cells: differentiation and functions. Clin Dev Immunol 2012;2012:925135 doi:10.1155/2012/925135, 2012. PubMed: 22474485

Doorduijn EM, et al. CD4+ T cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy. Cancer Immunol Res 5(8): 642-653, 2017. doi: 10.1158/2326-6066.CIR-16-0334, 2017. PubMed: 28637878